Molecular tumor board: The University of California San Diego Moores Cancer Center experience

Oncologist

Volumn 19, Issue 6, 2014, Pages 631-636

  Schwaederle, Maria ^a   Parker, Barbara A ^a,b   Schwab, Richard B ^a,b   Fanta, Paul T ^b   Boles, Sarah G ^b   Daniels, Gregory A ^b   Bazhenova, Lyudmila A ^b   Subramanian, Rupa ^b   Coutinho, Alice C ^a   Ojeda Fournier, Haydee ^c   Datnow, Brian ^c   Webster, Nicholas J ^b   Lippman, Scott M ^a,b   Kurzrock, Razelle ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Molecular profile; Molecular tumor board; Mutation; Personalized

Indexed keywords

ATM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PROTEIN P53; PROTEIN RET;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CENTER; CLINICAL ARTICLE; DIGESTIVE SYSTEM CANCER; DNA SEQUENCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MALE; MEDICAL EDUCATION; MOLECULAR DIAGNOSTICS; NECK CANCER; NEOPLASM; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SCIENTIST; SEQUENCE ANALYSIS; DISEASE FREE SURVIVAL; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; MIDDLE AGED; MOLECULAR PATHOLOGY; NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE; TREATMENT OUTCOME;

AGED; DISEASE-FREE SURVIVAL; FEMALE; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATHOLOGY, MOLECULAR; PRECISION MEDICINE; TREATMENT OUTCOME;

EID: 84901918076     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0405     Document Type: Article

References (35)

1. Dancey JE, Bedard PL, Onetto N et al. Thegenetic basis for cancer treatment decisions. Cell 2012;148: 409-420
2. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-674
3. Wong KM, Hudson TJ, McPherson JD. Unraveling the genetics of cancer: Genome sequencing and beyond. Annu Rev Genomics Hum Genet 2011;12: 407-430
4. Barrett JC, Frigault MM, Hollingsworth S et al. Are companion diagnostics useful? Clin Chem 2013; 59:198-201
5. Montemurro F, Valabrega G, AgliettaM.Trastuzumab treatment in breast cancer. N Engl J Med 2006;354:2186-author reply 2186
6. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357: 39-51
7. Incorvati JA, Shah S, Mu Y et al. Targeted therapy for HER2 positive breast cancer. J Hematol Oncol 2013;6:38
8. Barbany G, Höglund M, Simonsson B. Complete molecular remission in chronic myelogenous leukemia after imatinib therapy. N Engl J Med 2002;347: 539-540
9. Boros LG, Lee W-NP, Cascante M. Imatinib and chronic-phase leukemias. N Engl J Med 2002;347: 67-68
10. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355: 2408-2417
11. Westin JR, Kurzrock R. It's about time: Lessons for solid tumors from chronic myelogenous leukemia therapy. Mol Cancer Ther 2012;11:2549-2555
12. Lee K-H, Lee K-Y, Jeon Y-J et al. Gefitinib in selected patients with pre-treated non-small-cell lung cancer: Results from a phase IV, multicenter, non-randomized study (SELINE). Tuberc Respir Dis (Seoul) 2012;73:303-311
13. Giaccone G. The role of gefitinib in lung cancer treatment. Clin Cancer Res 2004;10:4233s-4237s.
14. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancertogefitinib. N Engl J Med 2004;350:2129-2139
15. Moore MJ, Goldstein D, HammJ et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966
16. Santarpia M, De Pas TM, Altavilla G et al. Moving towards molecular-guided treatments: Erlotinib and clinical outcomes in non-small-cell lung cancer patients. Future Oncol 2013;9:327-345
17. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl JMed 2011;364: 2507-2516
18. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;365:1448-1450
19. Falchook GS, Long GV, Kurzrock R et al. Dabrafenib in patients withmelanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 2012;379: 1893-1901
20. Kwak EL, Bang Y-J, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703
21. Bang Y-J. The potential for crizotinib in nonsmall cell lung cancer: A perspective review. Ther Adv Med Oncol 2011;3:279-291
22. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. JNatl Compr Canc Netw 2011;9: 1335-1341
23. Gonzalez de Castro D, Clarke PA, Al-Lazikani B et al. Personalized cancer medicine: Molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther 2013;93:252-259
24. Said R, Hong DS, Warneke CL et al. P53 mutations in advanced cancers: Clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget 2013;4:705-714
25. Janku F, Wheler JJ, Naing A et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 2013;73: 276-284
26. Janku F, Berry DA, Gong J et al. Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. Clin Cancer Res 2012;18:6356-6363
27. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat ChemBiol 2006; 2:689-700
28. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: Successes, challenges and opportunities. Mol Oncol 2012;6:155-176
29. Tsimberidou A-M, Iskander NG, Hong DS et al. Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative. Clin Cancer Res 2012;18:6373-6383
30. Siddiqui AD, Piperdi B. KRAS mutation in colon cancer: A marker of resistance to EGFR-I therapy. Ann Surg Oncol 2010;17:1168-1176
31. Munoz J, Swanton C, Kurzrock R. Molecular Profiling and the Reclassification of Cancer: Divide and Conquer. Alexandria, VA: American Society of Clinical Oncology, 2013:127-134
32. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921
33. Braggio E, Egan JB, Fonseca R et al. Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J 2013;3:e127
34. Eisenstein M. Reading cancer's blueprint. Nat Biotechnol 2012;30:581-584
35. Vignot S, Frampton GM, Soria J-C et al. Nextgeneration sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with nonsmall- cell lung cancer. J Clin Oncol 2013;31: 2167-2172.